Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 4:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,546 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Girls, alone Clear all
Recruiting Phase 4 Interventional

GDM: Insulin with or Without Metformin?

NCT06781775
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Metformin + Insulin, Insulin
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 31, 2026, 4:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

NCT03610581
View directory record Official record
Conditions
Human Papillomavirus Infections
Interventions
Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 31, 2026, 4:12 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

NCT05797753
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Healthy Volunteer
Interventions
SAR443820, Erythromycin ethyl succinate, Itraconazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 31, 2026, 4:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Glycerol-Electrolyte Beverages on Fluid Balance in Healthy Euhydrated Men and Women at Rest

NCT06185595
View directory record Official record
Conditions
Hydration
Interventions
Beverage. Incomplete block where each participant will complete 3 of the 6 possible glycerol-sodium blends in random order.
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 31, 2026, 4:12 PM EDT
Terminated Phase 2 Interventional Results available

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

NCT00661531
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast, Neoplasms, Breast
Interventions
Estrace, Anastrozole
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Voorhees Township, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 31, 2026, 4:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Maternal Smoking Cessation and Pediatric Obesity Prevention

NCT03514602
View directory record Official record
Conditions
Childhood Obesity, Smoking, Cigarette, Pregnancy
Interventions
Multicomponent behavioral intervention, Education only control
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 31, 2026, 4:12 PM EDT
Completed No phase listed Observational

A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.

NCT00816530
View directory record Official record
Conditions
Breast Cancer
Interventions
Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography
Device
Lead sponsor
U-Systems, Inc.
Industry
Eligibility
25 Years and older · Female only
Enrollment
15,679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Indio, California • Monterey, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 31, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation

NCT02922127
View directory record Official record
Conditions
Contraception
Interventions
Ulipristal Acetate, Combined Oral Contraceptive Pill
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 31, 2026, 4:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety of a New Inserter Device for Paragard® (Intrauterine Copper Contraceptive)

NCT05309694
View directory record Official record
Conditions
Contraception
Interventions
Paragard® T380A Intrauterine Copper Contraceptive with New Inserter
Combination Product
Lead sponsor
CooperSurgical Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
8
States / cities
Denver, Colorado • South Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 4:12 PM EDT
Completed Not applicable Interventional

Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention

NCT07519200
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
SHARE-MC, Informational Booklet
Behavioral · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis

NCT06469164
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
BNT331, Placebo
Drug · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Marrero, Louisiana • Metairie, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.

NCT04936984
View directory record Official record
Conditions
Osteoporosis
Interventions
abaloparatide-sMTS (Patheon), abaloparatide-sMTS (Kindeva)
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 31, 2026, 4:12 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Intranasal Oxytocin on Appetite and Caloric Intake in Men and Women

NCT01513499
View directory record Official record
Conditions
Eating Behavior
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 31, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Imlunestrant (LY3484356) in Healthy Women

NCT05509816
View directory record Official record
Conditions
Healthy
Interventions
Midazolam, Imlunestrant
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 31, 2026, 4:12 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Pilot Study: Mobile Phone Based Physical Activity in Sedentary Men and Women

NCT01435564
View directory record Official record
Conditions
Sedentary Lifestyle, Physical Activity
Interventions
Mobile phone, pedometer only
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 69 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 31, 2026, 4:12 PM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

NCT05335993
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Peritoneal Cancer, Recurrent Carcinoma of Ovary, Adenocarcinoma of Ovary
Interventions
Oregovomab, Niraparib
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Durham, North Carolina • Oklahoma City, Oklahoma • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 31, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)

NCT03665038
View directory record Official record
Conditions
Post Partum Depression
Interventions
Brexanolone
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
15 Years to 17 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Tempe, Arizona • North Little Rock, Arkansas • Miramar, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 31, 2026, 4:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)

NCT06266416
View directory record Official record
Conditions
Sexually Transmitted Infections (Not HIV or Hepatitis), HIV Infections, Sexual Behavior
Interventions
IMARA for Black Male Caregivers and Girls Empowerment, Time-matched control program
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
13 Years and older
Enrollment
612 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 31, 2026, 4:12 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV

NCT07526948
View directory record Official record
Conditions
Menopausal Complaints, Vaginal Atrophy, Genitourinary Symptoms, HIV (Human Immunodeficiency Virus), Menopause Related Conditions, Vaginitis, Perimenopause
Interventions
Vaginal estradiol tablets, Vaginal moisturizer
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 31, 2026, 4:12 PM EDT
Completed Not applicable Interventional

Comparison of MRI and CEDM to Evaluate Treatment Response Before Surgery

NCT03070340
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast Magnetic Resonance Imaging (MRI), Contrast Enhanced Mammography (CEDM)
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 31, 2026, 4:12 PM EDT
Recruiting Not applicable Interventional

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

NCT04124120
View directory record Official record
Conditions
Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Interventions
Single arterial graft, Multiple arterial grafting
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
2,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
42
States / cities
Los Angeles, California • Pomona, California • San Francisco, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 31, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Results available

MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

NCT03767335
View directory record Official record
Conditions
Advanced or Metastatic Breast Cancer
Interventions
MEN1611, Trastuzumab, Fulvestrant
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Farmington Hills, Michigan • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 31, 2026, 4:12 PM EDT
Completed No phase listed Observational

Evaluation of Barriers to Postpartum Care in HIV Infected Women

NCT01853917
View directory record Official record
Conditions
HIV Infection, Pregnancy
Interventions
questionaires and structured interviews
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 31, 2026, 4:12 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women

NCT01634789
View directory record Official record
Conditions
Healthy
Interventions
bazedoxifene, bazedoxifene/conjugated estrogens
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 64 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 31, 2026, 4:12 PM EDT